S&P Futures
3,921.00 -1.75 (-0.04%) Dow Futures
31,437.00 -3.00 (-0.01%) Nasdaq Futures
11,913.25 -22.25 (-0.19%) Russell 2000 Futures
1,775.10 +2.30 (+0.13%) Crude Oil
110.19 +0.60 (+0.55%) Gold
1,814.20 -1.70 (-0.09%)
Verrica Pharmaceuticals Inc. (VRCA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 6.30 |
| Open | 6.30 |
| Bid | 6.06 x 900 |
| Ask | 6.65 x 800 |
| Day's Range | 6.09 - 6.36 |
| 52 Week Range | 5.20 - 14.79 |
| Volume | |
| Avg. Volume | 100,463 |
| Market Cap | 167.729M |
| Beta (5Y Monthly) | 1.97 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M
KemPharm (KMPH) inks deal to acquire Orphazyme A/S, which will add to its portfolio the latter's pipeline candidate, arimoclomol, being developed for treating Niemann-Pick disease type C. Shares rise.
- Zacks
After Plunging 28.5% in 4 Weeks, Here's Why the Trend Might Reverse for Verrica Pharmaceuticals Inc. (VRCA)
The heavy selling pressure might have exhausted for Verrica Pharmaceuticals Inc. (VRCA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- Zacks
Here's Why Verrica Pharmaceuticals Inc. (VRCA) is Poised for a Turnaround After Losing 31.6% in 4 Weeks
The heavy selling pressure might have exhausted for Verrica Pharmaceuticals Inc. (VRCA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
